Shahriar Dadkhah, MD, MBA, FACC, FACP, FCCP, FSCAI
Dr. Shahriar Dadkhah is a board certified cardiologist. Dr. Dadkhah’s passion for medicine stems from his love of clinical research. Dr. Dadkhah has been conducting research since 1979 . He has authored over fifty publications in journals such as the American Journal of Cardiology, Angiology, Circulation, and Critical Pathways in Cardiology. He has also authored a chapter on the epidemiology and demography of coronary artery disease in the Short Stay Management of Chest Pain textbook, chapter on Heart Failure and Kidney disease in the Short Stay Management of Acute Heart Failure textbook and a chapter on Symptoms of Atrial Fibrillation in Short Stay Management of Atrial Fibrillation.
Through his research, Dr. Dadkhah has become a pioneer in diagnostic testing and protocol streamlining. In fact, in 1999 Dr. Dadkhah recommended that all patients with NSTEMI should be sent to the catheterization lab and he predicted in an interview with NBC News that by 2001 most hospital in the United States will use the cardiac marker Troponin I for diagnosing acute coronary syndromes. In 2004 the NEW ERA research study conducted by Dr. Dadkhah demonstrated that patients could be diagnosed with myocardial infarction in the pre-hospital setting by using a combination of 12 lead ECG and cardiac biomarkers in the field. His latest research study involves Value of Troponin in Transgender person.
Because of his work, Dr. Dadkhah has also received numerous awards including being named as one of Chicago’s Top Physician’s by Chicago Hospital News, he has awards from the Heart of Chicago and the American Association for Clinical Chemistry. Dr. Dadkhah is Professor of Medicine at the University of Illinois College of Medicine. In addition to his research and academic appointments, Dr. Dadkhah serves on numerous cardiology boards across the country. Dr. Dadkhah is past president of the Society of Chest Pain Centers part of American College of Cardiology which has accredited over 1000 hospitals worldwide.